Display options
Cite
Kotta S, Aldawsari HM, Badr-Eldin SM, et al. Exploring the Potential of Carbon Dots to Combat COVID-19. Front Mol Biosci. 2020;7:616575doi: 10.3389/fmolb.2020.616575.
Kotta, S., Aldawsari, H. M., Badr-Eldin, S. M., Alhakamy, N. A., Md, S., Nair, A. B., & Deb, P. K. (2020). Exploring the Potential of Carbon Dots to Combat COVID-19. Frontiers in molecular biosciences, 7616575. https://doi.org/10.3389/fmolb.2020.616575
Kotta, Sabna, et al. "Exploring the Potential of Carbon Dots to Combat COVID-19." Frontiers in molecular biosciences vol. 7 (2020): 616575. doi: https://doi.org/10.3389/fmolb.2020.616575
Kotta S, Aldawsari HM, Badr-Eldin SM, Alhakamy NA, Md S, Nair AB, Deb PK. Exploring the Potential of Carbon Dots to Combat COVID-19. Front Mol Biosci. 2020 Dec 17;7:616575. doi: 10.3389/fmolb.2020.616575. eCollection 2020. PMID: 33425995; PMCID: PMC7793735.
Copy Download .nbib Format: NLM
Share it on

Front Mol Biosci. 2020 Dec 17;7:616575. doi: 10.3389/fmolb.2020.616575. eCollection 2020.

Exploring the Potential of Carbon Dots to Combat COVID-19.

Frontiers in molecular biosciences

Sabna Kotta, Hibah Mubarak Aldawsari, Shaimaa M Badr-Eldin, Nabil A Alhakamy, Shadab Md, Anroop B Nair, Pran Kishore Deb

Affiliations

  1. Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.
  2. Department of Pharmaceutics and Industrial Pharmacy, Cairo University, Giza, Egypt.
  3. Center of Excellence for Drug Research and Pharmaceutical Industries, King Abdulaziz University, Jeddah, Saudi Arabia.
  4. Department of Pharmaceutics, King Abdulaziz University, Jeddah, Saudi Arabia.
  5. Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa, Saudi Arabia.
  6. Department of Pharmaceutical Sciences, Faculty of Pharmacy, Philadelphia University, Amman, Jordan.

PMID: 33425995 PMCID: PMC7793735 DOI: 10.3389/fmolb.2020.616575

Abstract

Viral diseases are considered as a global burden. The eradication of viral diseases is always a challenging task in medical research due to the high infectivity and mutation capability of the virus. The ongoing COVID-19 pandemic is still not under control even after several months of the first reported case and global spread. Neither a specific drug nor a vaccine is available for public use yet. In the pursuit of a promising strategy, carbon dots could be considered as potential nanostructure against this viral pandemic. This review explores the possibility of carbon nano-dots to combat COVID-19 based on some reported studies. Carbon dots are photoluminescent carbon nanoparticles, smaller than 10 nm in dimension with a very attractive photostable and biocompatible properties which can be surfaced modified or functionalized. These photoluminescent tiny particles have captured much attention owing to their functionalization property and biocompatibility. In response to this pandemic outbreak, this review attempts to summarize the potential use of carbon dots in antiviral therapy with particular emphasis on their probable role in the battlefront against COVID-19 including their possible biosensing applications.

Copyright © 2020 Kotta, Aldawsari, Badr-Eldin, Alhakamy, Md, Nair and Deb.

Keywords: COVID-19; SARS-CoV-2; antiviral; carbon dots; functionalization of carbon dots

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  1. J Fluoresc. 2015 Jul;25(4):803-10 - PubMed
  2. Adv Sci (Weinh). 2015 Feb 26;2(4):1500002 - PubMed
  3. Anal Sci. 2011;27(3):243-6 - PubMed
  4. Sci Rep. 2020 Apr 30;10(1):7343 - PubMed
  5. Angew Chem Int Ed Engl. 2007;46(34):6473-5 - PubMed
  6. Sci Rep. 2015 Jul 02;5:11835 - PubMed
  7. Biomed Pharmacother. 2020 Dec;132:110834 - PubMed
  8. Anal Chem. 2013 Nov 5;85(21):10232-9 - PubMed
  9. ACS Appl Mater Interfaces. 2018 Feb 7;10(5):4369-4378 - PubMed
  10. ACS Nano. 2020 Apr 28;14(4):3719-3720 - PubMed
  11. Chem Commun (Camb). 2012 Oct 7;48(77):9634-6 - PubMed
  12. Adv Mater. 2012 Apr 17;24(15):2037-41 - PubMed
  13. Biosens Bioelectron. 2017 Mar 15;89(Pt 2):773-780 - PubMed
  14. N Engl J Med. 2020 Mar 26;382(13):1199-1207 - PubMed
  15. Chem Commun (Camb). 2009 Sep 14;(34):5118-20 - PubMed
  16. Nanotechnology. 2014 Aug 8;25(31):315702 - PubMed
  17. Nanoscale. 2018 Jun 14;10(23):10991-10998 - PubMed
  18. Talanta. 2019 May 1;196:456-478 - PubMed
  19. J Control Release. 2018 Jan 10;269:302-321 - PubMed
  20. Environ Res. 2020 Dec;191:110119 - PubMed
  21. Appl Organomet Chem. 2020 Jun 26;:e5887 - PubMed
  22. Biosens Bioelectron. 2014 Oct 15;60:292-8 - PubMed
  23. Chem Sci. 2020 Jun 16;11(26):6606-6622 - PubMed
  24. ACS Appl Mater Interfaces. 2016 Jan 27;8(3):1951-7 - PubMed
  25. Anal Chem. 2012 Jul 17;84(14):6220-4 - PubMed
  26. Chem Soc Rev. 2015 Jan 7;44(1):362-81 - PubMed
  27. Biosens Bioelectron. 2016 Dec 15;86:83-89 - PubMed
  28. ACS Nano. 2017 Jul 25;11(7):6703-6716 - PubMed
  29. J Colloid Interface Sci. 2019 Apr 15;542:198-206 - PubMed
  30. Chem Rev. 2015 Jun 10;115(11):4744-822 - PubMed
  31. Clin Infect Dis. 2020 Jul 28;71(15):769-777 - PubMed
  32. Small. 2016 Sep;12(34):4713-8 - PubMed
  33. Int J Pharm. 2018 Sep 5;548(1):540-558 - PubMed
  34. J Am Chem Soc. 2004 Oct 13;126(40):12736-7 - PubMed
  35. Anal Chem. 2014 Sep 16;86(18):8902-5 - PubMed
  36. Nanoscale. 2011 May;3(5):2023-7 - PubMed
  37. Drug Discov Today. 2018 Jun;23(6):1219-1232 - PubMed
  38. Anal Chim Acta. 2012 Apr 20;723:83-7 - PubMed
  39. J Biomed Nanotechnol. 2011 Dec;7(6):846-8 - PubMed
  40. Sci Rep. 2017 Mar 31;7(1):519 - PubMed
  41. Nanoscale. 2013 Dec 7;5(23):11665-71 - PubMed
  42. Mater Sci Eng C Mater Biol Appl. 2020 Jul;112:110924 - PubMed
  43. Sci Rep. 2015 Nov 10;5:16403 - PubMed
  44. Small. 2019 Oct;15(41):e1902641 - PubMed
  45. ACS Appl Mater Interfaces. 2014 Mar 12;6(5):3365-70 - PubMed
  46. Nanoscale Res Lett. 2013 Mar 08;8(1):122 - PubMed
  47. Biomaterials. 2016 Nov;108:187-96 - PubMed
  48. ACS Appl Mater Interfaces. 2015 Aug 12;7(31):17054-60 - PubMed
  49. Mater Sci Eng C Mater Biol Appl. 2014 May 1;38:20-7 - PubMed
  50. Drug Discov Today. 2018 Feb;23(2):235-250 - PubMed
  51. Small. 2020 Apr;16(13):e1906206 - PubMed
  52. Front Bioeng Biotechnol. 2020 Apr 02;8:258 - PubMed
  53. ACS Appl Mater Interfaces. 2018 Aug 15;10(32):26936-26946 - PubMed
  54. Travel Med Infect Dis. 2020 Sep - Oct;37:101755 - PubMed
  55. ACS Appl Mater Interfaces. 2019 Nov 20;11(46):42964-42974 - PubMed
  56. Nano Today. 2020 Dec;35:101001 - PubMed
  57. Int J Nanomedicine. 2020 Aug 28;15:6519-6529 - PubMed
  58. Angew Chem Int Ed Engl. 2010 Sep 10;49(38):6726-44 - PubMed
  59. Nano Today. 2020 Aug;33:100883 - PubMed
  60. Curr Med Chem. 2021;28(2):284-307 - PubMed
  61. Luminescence. 2015 Jun;30(4):420-4 - PubMed
  62. Cytokine Growth Factor Rev. 2020 Jun;53:25-32 - PubMed
  63. ACS Appl Mater Interfaces. 2016 Apr 13;8(14):9004-13 - PubMed
  64. J Mater Chem B. 2014 Jul 28;2(28):4564-4571 - PubMed

Publication Types